227 related articles for article (PubMed ID: 36230530)
1. Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma.
Zarrabi KK; Lanade O; Geynisman DM
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230530
[TBL] [Abstract][Full Text] [Related]
2. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
3. Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions.
Govindarajan A; Castro DV; Zengin ZB; Salgia SK; Patel J; Pal SK
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565179
[TBL] [Abstract][Full Text] [Related]
4. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma.
Argentiero A; Solimando AG; Krebs M; Leone P; Susca N; Brunetti O; Racanelli V; Vacca A; Silvestris N
J Clin Med; 2020 May; 9(5):. PubMed ID: 32456352
[TBL] [Abstract][Full Text] [Related]
6. Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review.
Navani V; Heng DYC
JAMA Oncol; 2022 Feb; 8(2):292-299. PubMed ID: 34792538
[TBL] [Abstract][Full Text] [Related]
7. Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era.
Schmidt AL; Tabakin AL; Singer EA; Choueiri TK; McKay RR
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-11. PubMed ID: 33793313
[TBL] [Abstract][Full Text] [Related]
8. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
9. Towards individualized therapy for metastatic renal cell carcinoma.
Kotecha RR; Motzer RJ; Voss MH
Nat Rev Clin Oncol; 2019 Oct; 16(10):621-633. PubMed ID: 30992569
[TBL] [Abstract][Full Text] [Related]
10. The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.
Zhang T; Hwang JK; George DJ; Pal SK
Cancer Treat Res Commun; 2020; 24():100183. PubMed ID: 32563923
[TBL] [Abstract][Full Text] [Related]
11. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
[TBL] [Abstract][Full Text] [Related]
12. Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios.
Cetin B; Kosar A
Int Urol Nephrol; 2019 Dec; 51(12):2107-2117. PubMed ID: 31468288
[TBL] [Abstract][Full Text] [Related]
13. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
14. Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Apr; 51(5):793-801. PubMed ID: 33324983
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
16. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
17. An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma.
Dudani S; Savard MF; Heng DYC
Eur Urol Focus; 2020 Jan; 6(1):34-36. PubMed ID: 31010693
[TBL] [Abstract][Full Text] [Related]
18. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
20. Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy.
Grivas P; Yu EY
Curr Treat Options Oncol; 2019 Jun; 20(8):67. PubMed ID: 31254108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
